BIOCRYST PHARMACEUTICALS INC (BCRX)
BIOCRYST PHARMACEUTICALS INC (BCRX) from its SEC filings: 2025 revenue $874.8 million (+94% vs the year before), net margin 30%, free cash flow $347.4 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $874.8 million |
| Revenue growth | +94% |
| Net income | $263.9 million |
| Net margin | 30.2% |
| Free cash flow | $347.4 million |
| Diluted EPS | $1.21 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +34% |
| Cash | $155.0 million |
| Long-term debt | $395.4 million |
| Share count, 1 year | +22% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.